'We're Not There Yet': CAR T-Cell Therapy for Renal Cell Carcinoma

(MedPage Today) -- NASHVILLE, Tenn. -- Chimeric antigen receptor (CAR) T-cell therapy has the potential to become standard-of-care therapy for renal cell carcinoma (RCC) that does not respond to current therapies, an RCC specialist said here...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news